S-1: Silexion Therapeutics Files for Potential $15 Million Share Offering via Equity Line of Credit

Silexion Therapeutics aims to raise up to $15 million through an equity line of credit with White Lion Capital, as detailed in a recent S-1 filing.

Summary

• Silexion Therapeutics Corp, a clinical-stage biotechnology company, has filed a registration statement for the potential offer and sale of 15,337,500 ordinary shares.
• These shares may be issued to White Lion Capital, LLC, through an equity line of credit established by the Ordinary Share Purchase Agreement dated August 13, 2024.
• The agreement allows Silexion to sell up to $15.0 million in ordinary shares to White Lion until December 31, 2025.
• The shares consist of 15.0 million Purchased Shares and 337,500 Commitment Fee Shares.
• Silexion will not receive any proceeds from the sale of shares by White Lion, but may receive up to $15.0 million from the sale of Purchased Shares to White Lion.
• The actual proceeds may be less depending on the number of shares sold and the price at which they are sold.
• The Selling Shareholder is an underwriter within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended.
• On September 3, 2024, the last reported sales price of Silexion's ordinary shares was $1.10 per share and the last reported sales price of its warrants was $0.0801 per warrant.
• Silexion is an emerging growth company and has elected to comply with reduced public company reporting requirements.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While it highlights the potential for future revenue through the equity line of credit, it also acknowledges significant risks, ongoing losses, and the need for additional funding. The company's dependence on the success of its product candidates and the competitive landscape contribute to a cautious outlook.

Positives

• The equity line of credit provides Silexion with a potential source of funding to advance its clinical programs.
• The agreement with White Lion allows for flexibility in raising capital, with options for Rapid Purchase Notices and Jumbo Purchase Notices.
• BfArM agreed, in principle, to the design of the Phase 2/3 trial.

Negatives

• Silexion will not receive any proceeds from the resale of ordinary shares by the Selling Shareholder.
• The actual proceeds from White Lion may be less than $15.0 million.
• The issuance of ordinary shares to White Lion may cause substantial dilution to existing shareholders.
• The sale of shares acquired by White Lion could cause the price of Silexion's ordinary shares to decline.
• Silexion has broad discretion in the use of the net proceeds and may not use them effectively.

Risks

• Silexion has never generated any revenue from product sales and may never be profitable.
• The Company will need to raise substantial additional funding, which may not be available on acceptable terms, or at all, and which will cause dilution to its shareholders.
• Silexion is a development-stage company and has a limited operating history on which to assess its business.
• The approach Silexion is taking to discover and develop novel RNAi therapeutics is unproven for oncology and may never lead to marketable products.
• It is not possible to predict the actual number of shares we will sell under the White Lion Purchase Agreement to the Selling Shareholder or the actual gross proceeds resulting from those sales.
• Investors who buy shares in this offering at different times will likely pay different prices.
• If the Company fails to meet all applicable requirements of Nasdaq, and Nasdaq determines to delist the ordinary shares, the delisting could adversely affect the market liquidity of our ordinary shares and the market price of our ordinary shares could decrease.

Future Outlook

Silexion plans to conduct a Phase 2/3 trial of SIL-204B and initiate toxicology studies in 2025, followed by a regulatory submission in late 2025.

Industry Context

The document highlights the competitive landscape in the biotechnology and pharmaceutical industries, particularly in the development of novel drugs and technology platforms targeting KRAS mutations.

Comparison to Industry Standards

• The document mentions competition from companies like Bristol-Myers Squibb, Revolution Medicines, AstraZeneca, Boehringer, and Gilead, which are also developing treatments targeting KRAS mutations.
• The document notes that treatments for cancer currently include surgery, radiation therapy, chemotherapy, hormone therapy, immunotherapy and combined treatment modalities such as chemo-radiotherapy.
• The document mentions competition with companies working to develop antisense-based drugs, such as Ionis Pharmaceuticals, Inc.

Stakeholder Impact

• Shareholders may experience dilution due to the potential issuance of shares to White Lion.
• The success of Silexion's product candidates will impact the value of shareholders' investments.
• Employees' job security and compensation may be affected by the company's financial performance and ability to secure funding.

Next Steps

• Silexion plans to initiate toxicology studies of SIL-204B in 2025.
• Silexion plans to make a regulatory submission in late 2025 to initiate the Phase 2/3 trial.
• Silexion expects to apply for Orphan Drug Designation in both the U.S. and EU for its SIL-204B product in 2024.

Key Dates

Keywords

equity line of credit, Silexion Therapeutics, White Lion Capital, ordinary shares, capital raise, RNAi therapeutics, clinical stage, oncology, SIL-204B, KRAS